商品描述
Neurodegenerative disorders are rising worldwide, yet most approved drugs merely temper symptoms. Nucleic Acids and Precision Therapies for Neuroprotection addresses this therapeutic shortfall directly, tracing how antisense oligonucleotides, RNA interference agents, mRNA platforms, aptamers, and CRISPR-class editors are redefining what "treatable" means for Alzheimer's, Parkinson's, ALS, Huntington's disease, and Multiple Sclerosis.
Rather than cataloguing modalities in isolation, the book lays out an end-to-end translational roadmap from target identification and sequence optimisation to blood-brain barrier traversal, immunogenicity management, scalable manufacturing, and ethical oversight. Delivery science (including viral, nanoparticle, and hybrid vectors), AI-enabled biomarker discovery, adaptive trial architectures, and shifting global regulatory frameworks are viewed as interlocking elements of a single development pathway.
By aligning disparate scientific "dialects" into a shared, practice-oriented language, Nucleic Acids and Precision Therapies for Neuroprotection offers what the field currently lacks: a cohesive guide for moving nucleic acid therapeutics from concept to clinic with precision. Researchers, clinicians, regulators, and industry teams will find pragmatic frameworks, comparative tables, and decision points that shorten the path between mechanistic insight and patient impact without sacrificing rigour or transparency.
KEY FEATURES:
- Integrates molecular design, delivery engineering, clinical trial strategy, and regulatory science into one end-to-end translational workflow for nucleic acid therapeutics in neurology
- Delivers disease-specific playbooks (AD, PD, ALS, HD, MS) that map genotype/phenotype data to actionable targets, modality selection, and delivery routes
- Embeds AI/ML-driven biomarker discovery, patient stratification, and manufacturability analytics alongside ethical, access, and cost considerations
商品描述(中文翻譯)
神經退行性疾病在全球範圍內日益增加，但大多數已批准的藥物僅能緩解症狀。《核酸與精準療法在神經保護中的應用》直接針對這一治療不足，追溯反義寡核苷酸、RNA 干擾劑、mRNA 平台、適體和 CRISPR 類編輯器如何重新定義阿茲海默症、帕金森病、肌萎縮側索硬化症 (ALS)、亨廷頓病和多發性硬化症的“可治療性”。
本書不僅僅是孤立地列舉各種療法，而是提供了一個從靶點識別和序列優化到血腦屏障穿越、免疫原性管理、可擴展製造和倫理監管的端到端轉化路線圖。遞送科學（包括病毒、納米顆粒和混合載體）、AI 驅動的生物標記發現、自適應試驗架構以及不斷變化的全球監管框架被視為單一開發路徑的相互關聯元素。
通過將不同的科學“方言”整合成一種共享的、以實踐為導向的語言，《核酸與精準療法在神經保護中的應用》提供了該領域目前所缺乏的：一個將核酸療法從概念推向臨床的凝聚性指南。研究人員、臨床醫生、監管機構和產業團隊將發現實用的框架、比較表和決策點，縮短機制洞察與患者影響之間的距離，而不犧牲嚴謹性或透明度。
主要特點：
- 將分子設計、遞送工程、臨床試驗策略和監管科學整合為一個針對神經學核酸療法的端到端轉化工作流程
- 提供針對特定疾病的操作手冊（阿茲海默症、帕金森病、肌萎縮側索硬化症、亨廷頓病、多發性硬化症），將基因型/表型數據映射到可行的靶點、療法選擇和遞送路徑
- 嵌入 AI/機器學習驅動的生物標記發現、患者分層和可製造性分析，並考慮倫理、可及性和成本問題
作者簡介
Dr. Trideva Sastri Koduru is a faculty member in pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, India. His PhD work pioneered the use of intranasal nanostructured lipid carriers for miRNA-based modulation of multiple sclerosis, supported by a Senior Research Fellowship from the ICMR's Innovation & Translation Research division. He specialises in nano-carrier platforms for nucleic acid delivery, with a focus on neurological and autoimmune disorders, and brings complementary strengths in formulation design, bioanalytical method validation, and pharmacokinetics. Dr Sastri has strong expertise in miRNA-based drug delivery systems. He has made significant contributions to the pharmaceutical and drug delivery community by publishing several peer-reviewed papers in reputable journals, as well as editing and authoring scholarly chapters and volumes with Academic Press, CRC Press, and Springer. Dr. Sastri's research focuses on nanoscience-aided drug carrier systems and the genetic complexities of autoimmune conditions. His dedication extends to developing efficient carrier systems for delivering nucleic acid therapies, mainly focused on neurological conditions. His forthcoming endeavours centre on crafting highly efficient, targeted carrier systems for delivering miRNA therapeutics, contributing substantially to the progressive landscape of pharmaceutical sciences.
作者簡介(中文翻譯)
Dr. Trideva Sastri Koduru 是印度邁索爾 JSS 高等教育與研究學院 JSS 藥學院的藥劑學教職員。他的博士研究開創了使用鼻內奈米結構脂質載體來調節與小 RNA (miRNA) 相關的多發性硬化症，並獲得了印度醫學研究理事會 (ICMR) 創新與轉譯研究部門的高級研究獎學金支持。他專注於核酸遞送的奈米載體平台，特別是針對神經系統和自體免疫疾病，並在配方設計、生物分析方法驗證和藥物動力學方面擁有互補的專業能力。Sastri 博士在基於 miRNA 的藥物遞送系統方面具有深厚的專業知識。他通過在知名期刊上發表多篇同行評審的論文，以及編輯和撰寫與 Academic Press、CRC Press 和 Springer 合作的學術章節和專著，對藥學和藥物遞送社群做出了重要貢獻。Sastri 博士的研究重點是奈米科學輔助的藥物載體系統以及自體免疫疾病的遺傳複雜性。他的奉獻精神延伸至開發高效的載體系統，以遞送核酸療法，主要針對神經系統疾病。他即將進行的工作集中於設計高效且具針對性的載體系統，以遞送 miRNA 治療藥物，對藥學科學的進步領域做出實質貢獻。
